The Diagnosis Value Of The Tumor Makers(AFP,CEA,CA19-9,Ca-125) For The Benign And Malignant Disease Of The Liver And Biliary

Objective:To investigate the clinical value of tumor marker AFP,CEA,CA-125 and CA19-9 in the diagnose of liver and biliary system diseases.Methods:we collected the relevant clinical data, such as tumor markers (AFP, CEA, CA19-9, CA-125), hepatitis, age and gender from the patients of the malignant liver disease (primary liver cell cancer, portal department bile duct carcinoma, intrahepatic bile duct carcinoma),liver benign diseases (intrahepatic bile duct, liver cyst, liver abscess), the bravery manager and the pancreatic head carcinoma patients from 2006 to 2010 to analysis.Results:Through the statistical analysis, when it is single tested, AFP is diagnostic utility bigger in HCC than other tumor makers except of the exclusion of biliary calculi, CA19-9 and CA - 125 is diagnostic utility bigger in HCC than other tumor maker for the diagnosis of biliary malignant tumor. Joint AFP, CEA, CA-125 testing can improve the sensitivity of the liver cancer and biliary malignant tumor. Improving the positive rates of the liver cancer and the malignant tumor of the biliary tree at the same time,the liver cancer has a relation with the Hepatitis B and the age.Conclusion : The combining AFP , CEA,CA-125 and CA19-9 examination has complementary function,which is superior to any single marker examination and can greatly increase the detecting rate of liver cancer. Meanwhile, combined with hepatitis b history, age and other factors, can further improve the positive rates of the liver and biliary malignant tumors.